The DOI matches its Crossref record; 85 of the 85 references it cites were found in a registry or an index.
The resurgence of platinum-based cancer chemotherapy
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761
Platinum Compounds: a New Class of Potent Antitumour Agents
ROSENBERG, B., VANCAMP, L., TROSKO, J. E., & MANSOUR, V. H. (1969) · Nature · doi:10.1038/222385a0 · Cited by 3,972
de Gramont, A., Figer, A., Seymour, M., Homerin, M., Hmissi, A., Cassidy, J., Boni, C., Cortes-Funes, H., Cervantes, A., Freyer, G., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.16.2938 · Cited by 3,815
Cisplatin: mode of cytotoxic action and molecular basis of resistance
Siddik, Z. H. (2003) · Oncogene · doi:10.1038/sj.onc.1206933 · Cited by 3,335
Inhibition of Cell Division in Escherichia coli by Electrolysis Products from a Platinum Electrode
ROSENBERG, B., VAN CAMP, L., & KRIGAS, T. (1965) · Nature · doi:10.1038/205698a0 · Cited by 3,049
Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer
Armstrong, D. K., Bundy, B., Wenzel, L., Huang, H. Q., Baergen, R., Lele, S., Copeland, L. J., Walker, J. L., & Burger, R. A. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052985 · Cited by 2,625
Goldberg, R. M., Sargent, D. J., Morton, R. F., Fuchs, C. S., Ramanathan, R. K., Williamson, S. K., Findlay, B. P., Pitot, H. C., & Alberts, S. R. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.09.046 · Cited by 2,249
Gradishar, W. J., Tjulandin, S., Davidson, N., Shaw, H., Desai, N., Bhar, P., Hawkins, M., & O'Shaughnessy, J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.937 · Cited by 2,153
Giacchetti, S., Perpoint, B., Zidani, R., Le Bail, N., Faggiuolo, R., Focan, C., Chollet, P., Llory, J. F., Letourneau, Y., Coudert, B., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.1.136 · Cited by 1,403
SISSAOUI, M. (2018) · Archives of Clinical Microbiology · doi:10.4172/1989-8436-c3-011 · Cited by 1,349
Fichtinger-Schepman, A. M. J., Van der Veer, J. L., Den Hartog, J. H. J., Lohman, P. H. M., & Reedijk, J. (1985) · Biochemistry · doi:10.1021/bi00324a025 · Cited by 1,024
Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals
Ishida, S., Lee, J., Thiele, D. J., & Herskowitz, I. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162491399 · Cited by 927
Takahara, P. M., Rosenzweig, A. C., Frederick, C. A., & Lippard, S. J. (1995) · Nature · doi:10.1038/377649a0 · Cited by 769
The ATP-dependent glutathione S-conjugate export pump
Ishikawa, T. (1992) · Trends in Biochemical Sciences · doi:10.1016/0968-0004(92)90489-v · Cited by 654
Rothenberg, M. L., Oza, A. M., Bigelow, R. H., Berlin, J. D., Marshall, J. L., Ramanathan, R. K., Hart, L. L., Gupta, S., Garay, C. A., Burger, B. G., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.11.126 · Cited by 646
Rixe, O., Ortuzar, W., Alvarez, M., Parker, R., Reed, E., Paull, K., & Fojo, T. (1996) · Biochemical Pharmacology · doi:10.1016/s0006-2952(97)81490-6 · Cited by 615
Overexpression of Metallothionein Confers Resistance to Anticancer Drugs
Kelley, S. L., Basu, A., Teicher, B. A., Hacker, M. P., Hamer, D. H., & Lazo, J. S. (1988) · Science · doi:10.1126/science.3175622 · Cited by 601
The role of DNA mismatch repair in platinum drug resistance.
Fink, D. A., Nebel, S., Aebi, S. P., Zheng, H., Cenni, B., Nehmé, A., Christen, R. D., & Howell, S. B. (1996) · PubMed · Cited by 597
Bhattacharyya, A., Ear, U. S., Koller, B. H., Weichselbaum, R. R., & Bishop, D. K. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.c000276200 · Cited by 583
Cellular accumulation of the anticancer agent cisplatin: A review
Gately, D., & Howell, S. (1993) · British Journal of Cancer · doi:10.1038/bjc.1993.221 · Cited by 572
Knox, R. J., Friedlos, F., Lydall, D. A., & Roberts, J. J. (1986) · PubMed · Cited by 498
Plumb, J. A., Strathdee, G. R., Sludden, J., Kaye, S. B., & Brown, R. E. (2000) · PubMed · doi:10.25405/ncl.34284429 · Cited by 486
Beuvink, I., Boulay, A., Fumagalli, S., Zilbermann, F., Ruetz, S., O’Reilly, T., Natt, F., Hall, J., Lane, H. A., & Thomas, G. (2005) · Cell · doi:10.1016/j.cell.2004.12.040 · Cited by 486
Cellular and molecular pharmacology of oxaliplatin.
Raymond, É., Faivre, S. J., Chaney, S. G., WOYNAROWSKI, J. M., & Cvitkovic, E. (2002) · PubMed · Cited by 463
Pietras, R. J., FENDLY, B. M., Chazin, V. R., Pegram, M. D., Howell, S. B., & Slamon, D. J. (1994) · PubMed · Cited by 437
Machover, D., Diaz-Rubio, E., de Gramont, A., Schilf, A., Gastiaburu, J.-J., Brienza, S., Itzhaki, M., Metzger, G., N'Daw, D., Vignoud, J., et al. (1996) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a010489 · Cited by 434
Gordon, A. N., Tonda, M., Sun, S., & Rackoff, W. (2004) · Gynecologic Oncology · doi:10.1016/j.ygyno.2004.07.011 · Cited by 422
Houghton, A. N., & Polsky, D. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00161-7 · Cited by 414
Activation of programmed cell death by anticancer agents: cisplatin as a model system.
Eastman, A. R. (1990) · PubMed · Cited by 398
New approaches to molecular cancer therapeutics
Collins, I., & Workman, P. (2006) · Nature Chemical Biology · doi:10.1038/nchembio840 · Cited by 391
Curing metastatic testicular cancer
Einhorn, L. H. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.072067999 · Cited by 387
Samimi, G., Safaei, R., Katano, K., Holzer, A. K., Rochdi, M., Tomioka, M., Goodman, M., & Howell, S. B. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0137 · Cited by 358
Lévi, F., Misset, J.-L., Brienza, S., Adam, R., Metzger, G., Itzakhi, M., Caussanel, J.-P., Kunstlinger, F., Lecouturier, S., Descorps-Declère, A., et al. (1992) · Cancer · doi:10.1002/1097-0142(19920215)69:4<893::aid-cncr2820690410>3.0.co;2-x · Cited by 343
Holzer, A. K., Manorek, G. H., & Howell, S. B. (2006) · Molecular Pharmacology · doi:10.1124/mol.106.022624 · Cited by 322
Solution Structure of a Cisplatin-Induced DNA Interstrand Cross-Link
Huang, H., Zhu, L., Reid, B. R., Drobny, G. P., & Hopkins, P. B. (1995) · Science · doi:10.1126/science.270.5243.1842 · Cited by 314
ERCC1 and ERCC2 Expression in Malignant Tissues From Ovarian Cancer Patients
Dabholkar, M., Bostick-Bruton, F., Weber, C., Bohr, V. A., Egwuagu, C., & Reed, E. (1992) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/84.19.1512 · Cited by 305
Köberle, B., Masters, J. R. W., Hartley, J. A., & Wood, R. D. (1999) · Current Biology · doi:10.1016/s0960-9822(99)80118-3 · Cited by 300
Katano, K., Kondo, A., Safaei, R., Holzer, A. K., Samimi, G., Mishima, M., Kuo, Y., Rochdi, M., & Howell, S. B. (2002) · PubMed · Cited by 290
Reardon, J. T., Vaisman, A., Chaney, S. G., & Sancar, A. (1999) · PubMed · Cited by 281
Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells
Ferry, K. V., Hamilton, T. C., & Johnson, S. W. (2000) · Biochemical Pharmacology · doi:10.1016/s0006-2952(00)00441-x · Cited by 275
Pegram, M. D., Pienkowski, T., Northfelt, D. W., Eiermann, W., Patel, R., Fumoleau, P., Quan, E., Crown, J., Toppmeyer, D., Smylie, M., et al. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh133 · Cited by 271
Gifford, G., Paul, J., Vasey, P. A., Kaye, S. B., Brown, R., & on behalf of the Scottish Gynaecological Clinical Trials Group (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0732 · Cited by 262
Mistry, P., Kelland, L., Abel, G., Sidhar, S., & Harrap, K. (1991) · British Journal of Cancer · doi:10.1038/bjc.1991.279 · Cited by 261
Self-citationImprovement of Cis-dichlorodiammineplatinum (NSC 119875): Therapeutic index in an animal model
Cvitkovic, E., Spaulding, J., Bethune, V., Martin, J., & Whitmore, W. F. (1977) · Cancer · doi:10.1002/1097-0142(197704)39:4<1357::aid-cncr2820390402>3.0.co;2-c · Cited by 259
Preclinical studies identifying carboplatin as a viable cisplatin alternative
Harrap, K. R. (1985) · Cancer Treatment Reviews · doi:10.1016/0305-7372(85)90015-5 · Cited by 259
Hurley, J., Doliny, P., Reis, I., Silva, O., Gomez-Fernandez, C., Velez, P., Pauletti, G., Powell, J. E., Pegram, M. D., & Slamon, D. J. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.8886 · Cited by 245
Antitumor activity of 1,2-diaminocyclohexaneplatinum complexes against Sarcoma-180 ascites form
Kidani, Y., Inagaki, K., Iigo, M., Hoshi, A., & Kuretani, K. (1978) · Journal of Medicinal Chemistry · doi:10.1021/jm00210a029 · Cited by 239
Advanced Ovarian Cancer Trialists' Group, Aabo, K., Adams, M., Adnitt, P., Alberts, D., Athanazziou, A., Barley, V, Bell, D., Bianchi, U., Bolis, G., et al. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.710 · Cited by 234
Kèlland, L. R., Abel, G., McKeage, M. J., Jones, M., Goddard, P. M., Valenti, M., Murrer, B. A., & Harrap, K. R. (1993) · PubMed · Cited by 224
Lewis, A. D., Hayes, J. D., & Wolf, C. R. (1988) · Carcinogenesis · doi:10.1093/carcin/9.7.1283 · Cited by 223
Reduced levels of XPA, ERCC1 and XPF DNA repair proteins in testis tumor cell lines
Welsh, C., Day, R., McGurk, C., Masters, J. R. W., Wood, R. D., & Köberle, B. (2004) · International Journal of Cancer · doi:10.1002/ijc.20134 · Cited by 215
Rademaker-Lakhai, J. M., Terret, C., Howell, S. B., Baud, C. M., de Boer, R. F., Pluim, D., Beijnen, J. H., Schellens, J. H. M., & Droz, J.-P. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0315 · Cited by 214
Spingler, B., Whittington, D. A., & Lippard, S. J. (2001) · Inorganic Chemistry · doi:10.1021/ic010790t · Cited by 207
A Role for Polymerase η in the Cellular Tolerance to Cisplatin-Induced Damage
Albertella, M. R., Green, C. M., Lehmann, A. R., & O'Connor, M. J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1095 · Cited by 207
Sternberg, C. N., Whelan, P., Hetherington, J., Paluchowska, B., Slee, P. H. T. J., Vekemans, K., van Erps, P., Theodore, C., Koriakine, O., Oliver, T., et al. (2005) · Oncology · doi:10.1159/000084201 · Cited by 206
Holford, J., Sharp, S., Murrer, B., Abrams, M., & Kelland, L. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.59 · Cited by 196
Self-citationTargeting the DNA repair defect of BRCA tumours
TURNER, N., TUTT, A., & ASHWORTH, A. (2005) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2005.03.006 · Cited by 164
White, S. C., Lorigan, P. C., Margison, G. P., Margison, J. M., Martin, F., Thatcher, N., Anderson, H., & Ranson, M. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603345 · Cited by 152
Role of the Glutathione Metabolic Pathway in Lung Cancer Treatment and Prognosis: A Review
Yang, P., Ebbert, J. O., Sun, Z., & Weinshilboum, R. M. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.7110 · Cited by 151
Roberts, D., Schick, J. S., Conway, S. R., Biade, S., Laub, P. B., Stevenson, J. P., Hamilton, T. C., O'Dwyer, P. J., & Johnson, S. W. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602447 · Cited by 142
Dragovich, T., Mendelson, D. S., Kurtin, S. E., Richardson, K., Hoff, D. D. V., & Hoos, A. (2006) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-006-0235-4 · Cited by 142
The Internalization and Degradation of Human Copper Transporter 1 following Cisplatin Exposure
Holzer, A. K., & Howell, S. B. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1710 · Cited by 140
Johnson, S. W., Swiggard, P., Handel, L. M., Brennan, J. M., Godwin, A. K., Ozols, R. F., & Hamilton, T. C. (1994) · PubMed · Cited by 135
DNA Repair capacity and cisplatin sensitivity of human testis tumour cells
Köberle, B., Grimaldi, K. A., Sunters, A., Hartley, J. A., Kèlland, L. R., & Masters, J. R. (1997) · International Journal of Cancer · Cited by 132
Raynaud, F. I., Boxall, F. E., Goddard, P. M., Valenti, M. R., Jones, M. A., Murrer, B. A., Abrams, M., & Kèlland, L. R. (1997) · PubMed · Cited by 121
Rice, J. R., Gerberich, J. L., Nowotnik, D. P., & Howell, S. B. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2169 · Cited by 117
Campone, M., Rademaker-Lakhai, J. M., Bennouna, J., Howell, S. B., Nowotnik, D. P., Beijnen, J. H., & Schellens, J. H. M. (2007) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-006-0397-0 · Cited by 115
The role of copper transporters in the development of resistance to Pt drugs
Safaei, R., Holzer, A. K., Katano, K., Samimi, G., & Howell, S. B. (2004) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2004.05.006 · Cited by 114
MutS Preferentially Recognizes Cisplatin- over Oxaliplatin-modified DNA
Zdraveski, Z. Z., Mello, J. A., Farinelli, C. K., Essigmann, J. M., & Marinus, M. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m105382200 · Cited by 103
Mismatch repair and treatment resistance in ovarian cancer
Helleman, J., van Staveren, I. L., Dinjens, W. N. M., van Kuijk, P. F., Ruigrok-Ritstier, K., Ewing, P. C., van der Burg, M. E., Stoter, G., & Berns, E. M. J. J. (2006) · BMC Cancer · doi:10.1186/1471-2407-6-201 · Cited by 101
Protein interactions with platinum–DNA adducts: from structure to function
Chaney, S. G., Campbell, S. L., Temple, B. R. S., Bassett, E., Wu, Y., & Faldu, M. (2004) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2004.04.024 · Cited by 99
Chang, I. Y., Kim, M.-H., Kim, H.-B., Lee, D. Y., Kim, S., Kim, H.-Y., & You, H. J. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.12.008 · Cited by 91
Satraplatin: an orally available platinum analog for the treatment of cancer
Choy, H. (2006) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.6.7.973 · Cited by 88
Teuben, J., Bauer, C., Wang, A. H. ‐., & Reedijk, J. (1999) · Biochemistry · doi:10.1021/bi9904757 · Cited by 79
Morgan, A. S., Sanderson, P. E., Borch, R. F., Tew, K. D., Niitsu, Y., Takayama, T., Hoff, D. D. V., Izbicka, E., Mangold, G. L., Paul, C., et al. (1998) · PubMed · Cited by 76
Gadducci, A., Cosio, S., Muraca, S., & Genazzani, A. R. (2002) · PubMed · Cited by 75
Walker, M. C., Parris, C. N., & Masters, J. R. W. (1987) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/79.2.213 · Cited by 63
Morgan-Lappe, S. E., Woods, K. W., Li, Q., Anderson, M. G., Schurdak, M. E., Luo, Y., Giranda, V. L., Fesik, S. W., & Leverson, J. D. (2005) · Oncogene · doi:10.1038/sj.onc.1209169 · Cited by 53
Sharp, S. Y., O'Neill, C., Rogers, P., et al. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(02)00244-7 · Cited by 53
Kavanagh, J. J., Gershenson, D. M., Choi, H. J., et al. (2005) · International Journal of Gynecological Cancer · doi:10.1111/j.1525-1438.2005.00114.x · Cited by 52
Bassett, E., Vaisman, A., Leeman, K. T., McCall, C. M., Masutani, C., Hanaoka, F., & Chaney, S. G. (2002) · DNA repair · doi:10.1016/s1568-7864(02)00150-7 · Cited by 48
Beale, P. J., Judson, I. R., O’Donnell, A. E., Trigo, J. M., Rees, C., Raynaud, F. I., Turner, A., Simmons, L., & Etterley, L. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6600854 · Cited by 43
Olivero, M., Ruggiero, T., Saviozzi, S., Rasola, A., Coltella, N., Crispi, S., Cunto, F. D., Calogero, R., & Renzo, M. F. D. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0013 · Cited by 22
McKeage, M. J., & Kèlland, L. R. (2006) · American Journal of Cancer · doi:10.2165/00024669-200605030-00002 · Cited by 18
Cited by
Cisplatin in cancer therapy: Molecular mechanisms of action
Dasari, S., & Bernard Tchounwou, P. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.07.025 · Cited by 5,537
Molecular mechanisms of cisplatin resistance
Galluzzi, L., Senovilla, L., Vitale, I., Michels, J., Martins, I., Kepp, O., Castedo, M., & Kroemer, G. (2012) · Oncogene · doi:10.1038/onc.2011.384 · Cited by 2,760
Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy
Yu, T., Guo, F., Yu, Y., Sun, T., Ma, D., Han, J., Qian, Y., Kryczek, I., Sun, D., Nagarsheth, N., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.008 · Cited by 2,198
Mechanisms of DNA damage, repair, and mutagenesis
Chatterjee, N., & Walker, G. C. (2017) · Environmental and Molecular Mutagenesis · doi:10.1002/em.22087 · Cited by 2,039
The status of platinum anticancer drugs in the clinic and in clinical trials
Wheate, N. J., Walker, S., Craig, G. E., & Oun, R. (2010) · Dalton Transactions · doi:10.1039/c0dt00292e · Cited by 1,634
Metadata
- Authors
- Kelland, L.
- Venue
- Nature Reviews Cancer
- Published
- 2007-07-12
- Volume
- 7
- Issue
- 8
- Pages
- 573-584
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2130177169
- Cited by
- 4,717
- References
- 85
- FWCI
- 7.84
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.